Yujun Huang

Yujun Huang

Auto-generated profile, based on publicly available information

Yujun Huang

School of Environment, Tsinghua University, 100084, Beijing, PR China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Water Research
Verified
Journal Article
Closed access
YHYujun Huang
Yujun Huang
FMFanlin Meng
Fanlin Meng
SLShuming Liu
Shuming Liu
SSSiao Sun
Siao Sun
KSKate Smith
Kate Smith

3 February 2024 in Water Research
Verified
Journal Article
Closed access
XYXipeng Yu
Xipeng Yu
YWYipeng Wu
Yipeng Wu
FMFanlin Meng
Fanlin Meng
XZXiao Zhou
Xiao Zhou
SLShuming Liu
Shuming Liu
XWXue Wu
Xue Wu

7 August 2023 in Process Safety and Environmental Protection
Verified
Journal Article
Closed access
YWYipeng Wu
Yipeng Wu
XMXingke Ma
Xingke Ma
GGGuancheng Guo
Guancheng Guo
YHYujun Huang
Yujun Huang
MLMingyang Liu
Mingyang Liu
JFJingjing Fan
Jingjing Fan

17 November 2023 in Environmental Science & Technology
Verified
Journal Article
Closed access
YHYujun Huang
Yujun Huang
Yifan XieYifan Xie
Yifan Xie
YWYipeng Wu
Yipeng Wu
FMFanlin Meng
Fanlin Meng
CHChengyu He
Chengyu He
SLShuming Liu
Shuming Liu

22 April 2025 in Resources, Conservation and Recycling
Verified
Journal Article
Closed access
Yifan XieYifan Xie
Yifan Xie
YWYipeng Wu
Yipeng Wu
YHYujun Huang
Yujun Huang
YJYe Jin
Ye Jin
YLYuxian Li
Yuxian Li
SLShuming Liu
Shuming Liu

2 November 2023
Verified
Conference Paper
Open access
PDF file
PTPeggy A Thompson
Peggy A Thompson
PYPengyu Yang
Pengyu Yang
YHYujun Huang
Yujun Huang
SSSusan Song
Susan Song
LYLinette Yang
Linette Yang
Simon BaileySimon Bailey
Simon Bailey
Background Immune checkpoint inhibitors (CPI) have significantly advanced cancer treatment; nevertheless, responses are limited to patient subsets, thereby necessitating additional treatment strategies. Regulatory T-cells (Tregs) are a specialized population of CD4+ T-cells that maintain normal immune tolerance and homeostasis; however, in the tumor microenvironment (TME), Tregs are potent immunosuppressive cells that promote tumor immune evasion and reduced clinical response to CPI. The transcription factor IKZF2 is a marker of highly suppressive Tregs and is required to maintain a stable, suppressive Treg cell phenotype in the inflammatory TME. Depletion of IKZF2 reprograms suppressive Tregs into effector-like T-cells leading to anti-tumor immunity, but targeting transcription factors has been challenging due to the lack of defined structures and binding pockets. Protein degradation using the endogenous Ubiquitin Proteasome System (UPS) has enabled accessing undruggable proteins, such as IKZF2, through chemically induced proximity that promotes degradation. Methods Through computational modeling, compound screening and optimizing for enhanced reprogramming of Treg function, highly selective IKZF2 degraders were identified. Results PLX-4107 is a molecular glue that was designed to promote a novel interaction between IKZF2 and the E3 ubiquitin ligase substrate receptor, Cereblon, leading to potent and selective degradation of IKZF2. Degradation of IKZF2 by PLX-4107 is blocked by co-treating with proteasome and neddylation inhibitors or a Cereblon knock-out cell line, confirming that degradation is UPS mediated and dependent on Cereblon. Global cellular proteomics demonstrated that PLX-4107 selectively depleted IKZF2 protein levels without degrading other Cereblon neo-substrates. In vitro, PLX-4107 mediated degradation of IKZF2 caused human Tregs to lose their suppressive function and produce effector cytokines (IL2, IFNγ) resulting in increased proliferation of effector T-cells and tumor cell killing. Oral administration of PLX-4107 to primates or humanized mice demonstrated sustained depletion of IKZF2 and reprogramming of Tregs. In vivo xenograft efficacy studies showed that administration of PLX-4107 resulted in dose dependent single agent anti-tumor activity. PLX-4107 treatment resulted in destabilization of Tregs by decreasing CD25 expression and increasing Treg expression of effector-like cytokines leading to increased infiltration of activated CD4/8+ effector T-cells into tumor tissue. Co-administration of PLX-4107 and pembrolizumab in xenograft studies resulted in tumor growth inhibition and significant combination benefit. Conclusions PLX-4107 is a novel molecular glue that selectively degrades IKZF2, a transcription factor of suppressive Tregs. PLX-4107 mediated IKZF2 degradation reverses tumor immune evasion by converting Tregs to an effector-like T-cell phenotype, resulting in single agent antitumor activity and the ability to enhance CPI efficacy.